In non-small-cell lung cancer (NSCLC), programmed cell death ligand-1 (PD-L1) status is used to guide treatment decisions as a high PD-L1 score correlates with good response to immune checkpoint inhibition [6]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.